Acclivity Technologies, Inc.

Acclivity Technologies Inc, located in Raleigh, NC, is a discovery to preclinical health technologies company specializing in the development of novel small molecules for the treatment of cardiovascular, inflammatory, and ischemic diseases. Their lead drug candidate, ATI-0019, targets atherosclerotic and ischemic diseases and aims to reverse key processes driving cardiovascular disease. With a focus on peripheral artery disease and its manifestations, Acclivity Technologies is also building a library of related compounds and conducting in vitro and in vivo studies to establish the efficacy of ATI-0019.

Founded by Sandra Merkel-DeJames, PhD, CPC, and Kirk Pappan, PhD, MBA, Acclivity Technologies brings together a team with extensive experience in leadership roles across various industries, including pharma, diagnostics, health and wellness, and data and informatics. Driven by a vision of future technology development that includes drug device and diagnostic applications, the company aims to expand its pipeline to include other cardiovascular, inflammatory, and ischemic disease indications, as well as vasculitis and type 2 diabetes. With a strong focus on innovation and commercialization, Acclivity Technologies is dedicated to advancing the field of health technologies through cutting-edge research and development.

Generated from the website